NCT05250037
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
Active, Not Recruiting
Not specifiedAges 8+ObservationalFred Hutchinson Cancer CenterInvestigator-initiated
~261 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:Home spirometryBiospecimen CollectionQuestionnaire Administration
At a glance
Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of bronchiolitis obliterans syndrome (BOS)
Measured over Up to 2 years
+1 more outcome measured
Conditions
Where it's being run
4 sites across 4 statesCalifornia1
Michigan1
Texas1
Washington1
Study leadership
- Guang-Shing Cheng, MD · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Allogeneic HCT recipients with any indication, graft source, donor type, or conditioning regimen
Age 8 and older
a. Evidence of air trapping by PFTs: RV\>120%, or elevated RV/TLC (\>20% of predicted value)
b. High resolution chest CT with inspiratory and expiratory cuts that show findings that are consistent with small airways disease including (but not exclusive of) air trapping, bronchial wall thickening, or bronchiectasis. 3. BOS with atypical spirometric pattern
Patient should have an Android or iOS-based smartphone with reliable access to Wi-Fi for data to be transmitted electronically. Android smartphones should have a software version of 4.0 or higher; iOS phones should have a version of 8.0 or higher.
Patient should be willing and able to communicate electronically in English or Spanish.
Exclusion
Diagnosis of BOS at time of enrollment (Cohort 1 only)
Life expectancy \< 2 years.
Diagnosis of active hematologic relapse or malignancy requiring active treatment that will affect that patient's ability to comply with study procedures.
Patient should not have a clinically acute active lower respiratory tract infection or a clinically acute active noninfectious respiratory condition (i.e. COPD exacerbation, pleural effusion) at the time of enrollment. However, patient may become eligible once these conditions have stabilized or resolved as noted above.
Inability or unwillingness to perform the study procedures, most of which are performed at home.
Lack of a personal iOS or Android smartphone.
Inability or unwillingness to communicate electronically.
What this trial measures
- Incidence of bronchiolitis obliterans syndrome (BOS)Up to 2 years
Diagnosed by National Institute of Health criteria or clinical diagnosis in the absence of alternative diagnosis.
- Pulmonary impairmentUp to 2 years
Defined by temporal decline in forced expiratory volume in the first second (FEV1) determined by assessment of spirometry data.